Repligen Refinances 2028 Notes With $1B Convertible Issue at 0.25%
RGEN sits 87% above its 52-week low of $100.99.
Summary
Repligen is issuing $1.0 billion of 0.25% convertible senior notes due 2031, using roughly $541.4 million of the new notes to exchange for about $456.8 million of its 1.00% 2028 notes and selling the remaining $458.6 million for cash. The conversion price of about $226.37 is a 20% premium to the October 29 close, so dilution only bites well above current levels. The cash piece is the part that matters: about $120 million of net proceeds goes to buy back stock at $188.64, and the placement agent intends to buy roughly $30 million more, which supports the shares near the current price. Management frames this as pushing out the 2028 maturity, cutting interest expense and freeing capacity for BioLife integration and bolt-on M&A. Closing is expected on or about November 6, 2026, with about $143.2 million of the 2028 notes left outstanding on unchanged terms.
At the time of this announcement, RGEN was trading at $188.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12B. The 52-week trading range was $100.99 to $198.87. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.